Cargando…

Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia

Introduction: Benzotriazine-1,4-dioxides (BTDOs) such as tirapazamine (TPZ) and its derivatives act as radiosensitizers of hypoxic tissues. The benzotriazine-1-monoxide (BTMO) metabolite (SR 4317, TPZMO) of TPZ also has radiosensitizing properties, and via unknown mechanisms, is a potent enhancer of...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsaidi, Hassan, Ahmadi, Fatemeh, Wiebe, Leonard I., Kumar, Piyush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469288/
https://www.ncbi.nlm.nih.gov/pubmed/30609671
http://dx.doi.org/10.3390/ph12010003
_version_ 1783411617105444864
author Elsaidi, Hassan
Ahmadi, Fatemeh
Wiebe, Leonard I.
Kumar, Piyush
author_facet Elsaidi, Hassan
Ahmadi, Fatemeh
Wiebe, Leonard I.
Kumar, Piyush
author_sort Elsaidi, Hassan
collection PubMed
description Introduction: Benzotriazine-1,4-dioxides (BTDOs) such as tirapazamine (TPZ) and its derivatives act as radiosensitizers of hypoxic tissues. The benzotriazine-1-monoxide (BTMO) metabolite (SR 4317, TPZMO) of TPZ also has radiosensitizing properties, and via unknown mechanisms, is a potent enhancer of the radiosensitizing effects of TPZ. Unlike their 2-nitroimidazole radiosensitizer counterparts, radiolabeled benzotriazine oxides have not been used as radiopharmaceuticals for diagnostic imaging or molecular radiotherapy (MRT) of hypoxia. The radioiodination chemistry for preparing model radioiodinated BTDOs and BTMOs is now reported. Hypothesis: Radioiodinated 3-(2-iodoethoxyethyl)-amino-1,2,4-benzotriazine-1,4-dioxide (I-EOE-TPZ), a novel bioisosteric analogue of TPZ, and 3-(2-iodoethoxyethyl)-amino-1,2,4-benzotriazine-1-oxide (I-EOE-TPZMO), its monoxide analogue, are candidates for in vivo and in vitro investigations of biochemical mechanisms in pathologies that develop hypoxic microenvironments. In theory, both radiotracers can be prepared from the same precursors. Methods: Radioiodination procedures were based on classical nucleophilic [(131)I]iodide substitution on Tos-EOE-TPZ (P1) and by [(131)I]iodide exchange on I-EOE-TPZ (P2). Reaction parameters, including temperature, reaction time, solvent and the influence of pivalic acid on products’ formation and the corresponding radiochemical yields (RCY) were investigated. Results: The [(131)I]iodide labeling reactions invariably led to the synthesis of both products, but with careful manipulation of conditions the preferred product could be recovered as the major product. Radioiodide exchange on P2 in ACN at 80 ± 5 °C for 30 min afforded the highest RCY, 89%, of [(131)I]I-EOE-TPZ, which upon solid phase purification on an alumina cartridge gave 60% yield of the product with over 97% of radiochemical purity. Similarly, radioiodide exchange on P2 in ACN at 50 ± 5 °C for 30 min with pivalic acid afforded the highest yield, 92%, of [(131)I]I-EOE-TPZMO exclusively with no trace of [(131)I]I-EOE-TPZ. In both cases, extended reaction times and/or elevated temperatures resulted in the formation of at least two additional radioactive reaction products. Conclusions: Radioiodination of P1 and P2 with [(131)I]iodide leads to the facile formation of [(131)I]I-EOE-TPZMO. At 80 °C and short reaction times, the facile reduction of the N-4-oxide moiety was minimized to afford acceptable radiochemical yields of [(131)I]I-EOE-TPZ from either precursor. Regeneration of [(131)I]I-EOE-TPZ from [(131)I]I-EOE-TPZMO is impractical after reaction work-up.
format Online
Article
Text
id pubmed-6469288
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64692882019-04-24 Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia Elsaidi, Hassan Ahmadi, Fatemeh Wiebe, Leonard I. Kumar, Piyush Pharmaceuticals (Basel) Article Introduction: Benzotriazine-1,4-dioxides (BTDOs) such as tirapazamine (TPZ) and its derivatives act as radiosensitizers of hypoxic tissues. The benzotriazine-1-monoxide (BTMO) metabolite (SR 4317, TPZMO) of TPZ also has radiosensitizing properties, and via unknown mechanisms, is a potent enhancer of the radiosensitizing effects of TPZ. Unlike their 2-nitroimidazole radiosensitizer counterparts, radiolabeled benzotriazine oxides have not been used as radiopharmaceuticals for diagnostic imaging or molecular radiotherapy (MRT) of hypoxia. The radioiodination chemistry for preparing model radioiodinated BTDOs and BTMOs is now reported. Hypothesis: Radioiodinated 3-(2-iodoethoxyethyl)-amino-1,2,4-benzotriazine-1,4-dioxide (I-EOE-TPZ), a novel bioisosteric analogue of TPZ, and 3-(2-iodoethoxyethyl)-amino-1,2,4-benzotriazine-1-oxide (I-EOE-TPZMO), its monoxide analogue, are candidates for in vivo and in vitro investigations of biochemical mechanisms in pathologies that develop hypoxic microenvironments. In theory, both radiotracers can be prepared from the same precursors. Methods: Radioiodination procedures were based on classical nucleophilic [(131)I]iodide substitution on Tos-EOE-TPZ (P1) and by [(131)I]iodide exchange on I-EOE-TPZ (P2). Reaction parameters, including temperature, reaction time, solvent and the influence of pivalic acid on products’ formation and the corresponding radiochemical yields (RCY) were investigated. Results: The [(131)I]iodide labeling reactions invariably led to the synthesis of both products, but with careful manipulation of conditions the preferred product could be recovered as the major product. Radioiodide exchange on P2 in ACN at 80 ± 5 °C for 30 min afforded the highest RCY, 89%, of [(131)I]I-EOE-TPZ, which upon solid phase purification on an alumina cartridge gave 60% yield of the product with over 97% of radiochemical purity. Similarly, radioiodide exchange on P2 in ACN at 50 ± 5 °C for 30 min with pivalic acid afforded the highest yield, 92%, of [(131)I]I-EOE-TPZMO exclusively with no trace of [(131)I]I-EOE-TPZ. In both cases, extended reaction times and/or elevated temperatures resulted in the formation of at least two additional radioactive reaction products. Conclusions: Radioiodination of P1 and P2 with [(131)I]iodide leads to the facile formation of [(131)I]I-EOE-TPZMO. At 80 °C and short reaction times, the facile reduction of the N-4-oxide moiety was minimized to afford acceptable radiochemical yields of [(131)I]I-EOE-TPZ from either precursor. Regeneration of [(131)I]I-EOE-TPZ from [(131)I]I-EOE-TPZMO is impractical after reaction work-up. MDPI 2019-01-01 /pmc/articles/PMC6469288/ /pubmed/30609671 http://dx.doi.org/10.3390/ph12010003 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Elsaidi, Hassan
Ahmadi, Fatemeh
Wiebe, Leonard I.
Kumar, Piyush
Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
title Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
title_full Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
title_fullStr Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
title_full_unstemmed Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
title_short Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
title_sort development of [(131)i]i-eoe-tpz and [(131)i]i-eoe-tpzmo: novel tirapazamine (tpz)-based radioiodinated pharmaceuticals for application in theranostic management of hypoxia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469288/
https://www.ncbi.nlm.nih.gov/pubmed/30609671
http://dx.doi.org/10.3390/ph12010003
work_keys_str_mv AT elsaidihassan developmentof131iieoetpzand131iieoetpzmonoveltirapazaminetpzbasedradioiodinatedpharmaceuticalsforapplicationintheranosticmanagementofhypoxia
AT ahmadifatemeh developmentof131iieoetpzand131iieoetpzmonoveltirapazaminetpzbasedradioiodinatedpharmaceuticalsforapplicationintheranosticmanagementofhypoxia
AT wiebeleonardi developmentof131iieoetpzand131iieoetpzmonoveltirapazaminetpzbasedradioiodinatedpharmaceuticalsforapplicationintheranosticmanagementofhypoxia
AT kumarpiyush developmentof131iieoetpzand131iieoetpzmonoveltirapazaminetpzbasedradioiodinatedpharmaceuticalsforapplicationintheranosticmanagementofhypoxia